Loading...

Major Indexes

Financial Summary


Abbott Laboratories

Abbott Laboratories (ABT)

$92.97
0.74 (+0.80%)
Buy
A
Market Info
Financial Info
Financial Modelling
Symbol ABT
Price 92.97$
Beta 1.11
Volume Avrg. 8.01M
Market Cap 164.45B
Shares (2019) 1,781,000.00K
Last Div 1.36
Dividend Yield 1.39%
DCF Unlevered 52.51 Strong Sell
DCF Levered 64.92 Strong Sell
ROE 11.86% Buy
ROA 5.43% Neutral
Operating Margin 14.21% Buy
Debt / Equity 118.37% Buy
P/E 42.75 Strong Buy
P/B 5.07 Strong Buy

Income Statement

Quarter data
Download ABT income statement Download ABT income statement Download ABT income statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Earnings Per Share Diluted 3.712.963.013.721.621.492.920.940.271.332.06
Net Profit Margin -0.130.120.150.120.110.220.070.020.080.12
Weighted Average Shares Outstanding 1,546.981,546.401,557.641,575.381,558.001,516.001,496.001,477.001,740.001,758.001,768.00
Revenue 30,764,707.0035,166.7238,851.2639,873.9121,848.0020,247.0020,405.0020,853.0027,390.0030,578.0031,904.00
Weighted Average Shares Outstanding (Diluted) 1,555.131,556.021,567.391,591.841,574.001,527.001,506.001,483.001,749.001,770.001,781.00
Gross Profit 17,555,378.0020,501.5323,310.6824,754.1911,808.0011,029.0011,658.0011,829.0015,053.0017,872.0018,673.00
Dividend per Share -----------
Operating Income 1,447,936.006,087.585,751.958,084.522,629.002,599.002,867.003,185.001,726.003,650.004,532.00
Gross Margin 0.570.580.600.620.540.540.570.570.550.580.59
Income Tax Expense -1,086.66470.19299.69138.00797.00577.00350.001,878.00539.00390.00
EBIT Margin 0.090.250.230.270.200.200.210.230.210.230.24
Net Income -4,626.174,728.455,962.922,576.002,284.004,423.001,400.00477.002,368.003,687.00
Cost of Revenue 13,209,329.0014,665.1915,540.5815,119.7210,040.009,218.008,747.009,024.0012,337.0012,706.0013,231.00
Earnings Before Tax Margin -0.130.130.160.120.120.160.070.080.090.13
EBIT 1,447,936.006,087.585,751.958,084.522,629.002,599.002,867.003,185.001,726.003,650.004,532.00
EBITDA 2,658,913.008,711.898,795.8410,867.724,348.004,147.004,339.004,703.005,659.006,960.007,546.00
Profit Margin -0.130.120.150.120.110.220.070.020.080.12
Operating Expenses 24,528,966.0014,100.7516,886.2316,381.688,388.007,875.008,190.008,094.0011,352.0012,044.0012,205.00
Earnings Per Share Basic 3.712.983.033.761.641.502.940.940.271.342.07
Earnings before Tax -4,626.175,198.646,262.612,521.002,518.003,183.001,413.002,231.002,873.004,077.00
Interest Expense -519,656.00553.13530.14592.40157.00150.00163.00431.00904.00826.00670.00

Balance Sheet Statement

Quarter data
Download ABT balance shet statement Download ABT balance sheet statement Download ABT balance sheet statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Short-term debt 4,978,438.002,044.971,026.90308.829.0055.003.003.00508.007.001,277.00
Other Assets -------284.0012.00--
Total current liabilities 13,049,489.0017,262.4315,480.2313,280.189,507.0010,532.009,186.006,660.008,912.009,012.0010,863.00
Cash and cash equivalents 8,809,339.003,648.376,812.8210,802.163,475.004,063.005,001.0018,620.009,407.003,844.003,860.00
Long-term debt 211,182.0012,523.5212,039.8218,085.303,388.003,408.005,871.0020,681.0027,210.0019,359.0016,661.00
Cash and short-term investments 9,932,048.005,451.458,097.3615,173.983,475.004,460.006,125.0018,775.009,610.003,844.004,140.00
Total debt 11,477,476.0014,568.4913,066.7218,394.133,397.003,463.005,874.0020,684.0027,718.0019,366.0017,938.00
Inventories 3,264,877.003,188.733,284.253,792.312,693.002,643.002,599.002,434.003,601.003,796.004,316.00
Deferred revenue 2,364,142.003,076,051.002,700,540.002,986,216.002,528.001,705.002,119.0011.00-1,868.003,079.00
Goodwill and Intangible Assets 6,291,989.0028,081.7125,695.0224,362.4115,507.0016,265.0015,200.0012,222.0045,493.0042,196.0040,225.00
Total non-current liabilities 5,413,293.0022,799.4222,971.0630,127.7510,700.0010,701.0010,735.0025,230.0036,240.0019,359.0016,661.00
Total non-current assets 13,911,478.0037,144.7436,508.1235,912.3623,706.0026,014.0027,092.0025,890.0056,103.0052,541.0052,220.00
Total liabilities -37,074.1335,837.0640,513.9817,782.0019,749.0020,036.0032,128.0045,353.0036,649.0036,799.00
Total assets 37,225,369.0059,462.2760,276.8967,234.9442,953.0041,275.0041,247.0052,666.0076,250.0067,173.0067,887.00
Other comprehensive income 22,001,553.0023,754,981.0027,037,018.0030,314,639.0027,183.0026,579.0027,869.0027,801.0036,959.0038,110.0039,553.00
Short-term investments 1,122,709.001,803.081,284.544,371.827,589.00397.001,124.00155.00203.00242.00280.00
Property, Plant & Equipment Net 7,619,489.007,970.967,873.958,063.055,905.005,935.005,730.005,705.007,607.007,563.008,038.00
Net Debt 2,668,137.0010,920.126,253.907,591.96-78.00-600.00873.002,064.0018,311.0015,522.0014,078.00
Investments 1,122,709.002,105.131,662.764,645.427,589.00626.005,165.003,102.001,086.00242.001,163.00
Total shareholders equity 22,855,627.0022,388.1324,439.8326,720.9625,171.0021,526.0021,211.0020,538.0030,897.0030,524.0031,088.00
Retained earnings (deficit) -18,927.1020,907.3624,151.0021,979.0022,874.0025,757.0025,565.0023,978.0024,560.0025,847.00
Long-term investments -302.05378.23273.60-229.004,041.002,947.00883.00-883.00
Receivables -7,184.037,683.927,612.863,986.003,586.003,418.003,248.005,249.005,182.005,425.00
Payables 1,280,542.001,535.761,721.131,796.991,026.001,064.001,081.001,178.002,402.002,975.003,252.00
Total current assets 23,313,891.0022,317.5323,768.7731,322.5819,247.0015,261.0014,155.0026,776.0020,147.0014,632.0015,667.00

Cash Flow Statement

Quarter data
Download ABT cash flow statement Download ABT cash flow statement Download ABT cash flow statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Investing Cash Flow -3,698,710.00-12,188.32260.83-6,081.29-3,955.00-202.00406.00-248.00-9,618.00-1,472.00-1,815.00
Free Cash Flow 6,186,112.007,720.917,478.587,519.112,179.002,598.001,856.002,082.004,435.004,906.004,498.00
Depreciation & Amortization 1,210,977.002,624.303,043.892,783.211,719.001,548.001,472.001,518.003,933.003,310.003,014.00
Net cash flow / Change in cash 4,697,317.00-5,160.973,164.4510,802.16-7,327.00588.00938.0013,619.00-9,213.00-5,563.0016.00
Effect of forex changes on cash --620.89-43.0140.14-26.00-143.00-198.00-483.00116.00-116.00-16.00
Financing Cash Flow --1,087.74-6,023.45716.09-6,696.00-2,742.00-2,236.0011,147.00-5,281.00-10,391.00-4,289.00
Dividend payments -2,414,460.00-2,671.47-2,938.10-3,182.81-882.00-1,342.00-1,443.00-1,539.00-1,849.00-1,974.00-2,270.00
Stock-based compensation 366,357.00387.18382.60433.11262.00246.00292.00310.00406.00477.00519.00
Investment purchases -248,970.00-1,672.76-5,186.99-14,361.89-11,669.00-3,702.00-7,170.00-3,345.00-327.00-369.00-821.00
Acquisitions and disposals -2,370,630.00-9,433.24-672.50-1,227.47-580.00-3,317.00-235.00-80.00-17,183.00--170.00
Capital Expenditure 1,089,048.001,015.081,491.501,795.291,145.001,077.001,110.001,121.001,135.001,394.001,638.00
Operating Cash Flow 7,275,160.008,735.988,970.089,314.403,324.003,675.002,966.003,203.005,570.006,300.006,136.00

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) 509,310-18,92720,90724,15121,97922,87425,75725,56523,97824,560
Net Income -4,6264,7285,9632,5762,2844,4231,4004772,3683,687
Stock Dividends 1,905,15016,972190464-3,866-47-97-53-215188-130
Dividend Paid -2,414,460-2,671-2,938-3,183-882-1,342-1,443-1,539-1,849-1,974-2,270
Retained Earnings -18,92720,90724,15121,97922,87425,75725,56523,97824,56025,847

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE 90,8527,619,4897,9717,8748,0635,9055,9355,7305,7057,6077,563
Annual Depreciation 6,439,589-7,612,533-1,589-1,606-3,303-1,047-1,315-1,146767-1,438-1,163
Capital Expenditure 1,089,0481,0151,4921,7951,1451,0771,1101,1211,1351,3941,638
Net PPE 7,619,4897,9717,8748,0635,9055,9355,7305,7057,6077,5638,038

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -6,291,98928,08225,69524,36215,50716,26515,20012,22245,49342,196
New Purchases -248,970-1,673-5,187-14,362-11,669-3,702-7,170-3,345-327-369-821
Intangible and Goodwill 6,291,98928,08225,69524,36215,50716,26515,20012,22245,49342,19640,225

About


Mr. Robert B. Ford
Healthcare
Medical Devices
New York Stock Exchange

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Mnire's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood anal